Patents by Inventor Scott William Lowe

Scott William Lowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20200054640
    Abstract: A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.
    Type: Application
    Filed: August 19, 2019
    Publication date: February 20, 2020
    Inventors: Scott William LOWE, Charles J. SHERR, Chun-Hao HUANG, Amaia LUJAMBIO
  • Method and kits for identifying of CDK9 inhibitors for the treatment of cancer
    Patent number: 10383873
    Abstract: A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: August 20, 2019
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Scott William Lowe, Charles J. Sherr, Chun-Hao Huang, Amaia Lujambio
  • METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20170173021
    Abstract: A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.
    Type: Application
    Filed: April 2, 2015
    Publication date: June 22, 2017
    Inventors: Scott William LOWE, Charles J. SHERR, Chun-Hao HUANG, Amaia LUJAMBIO
  • Cell-free assay using oncogene-induced apoptosis to identify inhibitors of apoptosis in drug-resistant cells
    Patent number: 6670139
    Abstract: The present invention relates to a method of identifying a compound (agent) which modulates apoptosis in transformed cells. In one embodiment, the invention is a method of identifying a compound which selectively activates apoptosis in transformed cells. In an alternative embodiment, the present invention can be used as a method of identifying a compound which inhibits apoptosis in cells. The invention also relates to a method of selectively killing transformed cells, wherein the transformed cell is contacted with a compound which selectively activates apoptosis in transformed cells, as described herein. The invention also relates to methods of treating diseases associated with defective apoptotic machinery (e.g., cancer, neurodegenerative disease). The methods of the present invention are useful for defining the biochemical mechanisms of apoptosis.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: December 30, 2003
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Howard O. Fearnhead, Mila Elena McCurrach, Scott William Lowe, Yuri Lazebnik
  • Oncogene-induced apoptosis in drug-resistant cells
    Patent number: 6555330
    Abstract: The present invention relates to a method of identifying a compound (agent) which modulates apoptosis in transformed cells. In one embodiment, the invention is a method of identifying a compound which selectively activates apoptosis in transformed cells. In an alternative embodiment, the present invention can be used as a method of identifying a compound which inhibits apoptosis in cells. The invention also relates to a method of selectively killing transformed cells, wherein the transformed cell is contacted with a compound which selectively activates apoptosis in transformed cells, as described herein. The invention also relates to methods of treating diseases associated with defective apoptotic machinery (e.g., cancer, neurodegenerative disease). The methods of the present invention are useful for defining the biochemical mechanisms of apoptosis.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: April 29, 2003
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Howard O. Fearnhead, Mila Elena McCurrach, Scott William Lowe, Yuri Lazebnik
  • Cell-free assay using oncogene-induced apoptosis in drug-resistant cells
    Patent number: 5897992
    Abstract: The present invention relates to a method of identifying a compound (agent) which modulates apoptosis in transformed cells. In one embodiment, the invention is a method of identifying a compound which selectively activates apoptosis in transformed cells. In an alternative embodiment, the present invention can be used as a method of identifying a compound which inhibits apoptosis in cells. The invention also relates to a method of selectively killing transformed cells, wherein the transformed cell is contacted with a compound which selectively activates apoptosis in transformed cells, as described herein. The invention also relates to methods of treating diseases associated with defective apoptotic machinery (e.g., cancer, neurodegenerative disease). The methods of the present invention are useful for defining the biochemical mechanisms of apoptosis.
    Type: Grant
    Filed: September 27, 1996
    Date of Patent: April 27, 1999
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Howard O. Fearnhead, Mila Elena McCurrach, Scott William Lowe, Yuri Lazebnik